Transplantation and Cellular Therapy 

TL;DR: In this article , the outcomes of axi-cel therapy in the real-world setting were evaluated using multivariable logistic and Cox regressions, and the association with age, Eastern Cooperative Oncology Group Performance Score, and comorbidities were evaluated.

TL;DR: In this paper , the authors used the Vizient Clinical Database (CDB) to capture and analyze elective encounters for CAR T administration as well as encounters for any reason other than CART administration (non-CAR T) in patients with lymphoma, myeloma, and acute lymphoblastic leukemia.

TL;DR: In this paper , the authors evaluated the effect of consolidation hematopoietic cell transplantation (HCT) after CD19 chimeric antigen receptor (CAR) T cell therapy for patients with refractory/ relapsed B cell acute lymphoblastic leukemia.

TL;DR: In this paper , the authors used a novel assay to analyze patient and transplantation-related factors and their influence on immune responses to SARS-CoV-2 vaccination over an extended period (up to 6 months) in a large and homogenous group of allogeneic hematopoietic cell transplantation (allo-HCT).

TL;DR: In this paper , the authors present a multicenter retrospective study among centers that prescribe either commercial product to evaluate usage patterns, safety and efficacy outcomes, and resource utilization for axicabtagene ciloleucel and tisagenlecleucel (tisa-cel) recipients.